CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Shukla SA, Gusev A, Braun DA, Choueiri TK, Kwiatkowski DJ. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research 2021, 27: 4025-4035. PMID: 34074656, PMCID: PMC8900067, DOI: 10.1158/1078-0432.ccr-21-0575.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUrothelial carcinomaGenomic alterationsMemorial Sloan-Kettering Cancer CenterNon-small cell lungDana-Farber Cancer InstituteICI treatment outcomesPlatinum-based therapyTumor immune microenvironmentImmuno-inflammatory pathwaysRenal cell carcinomaDFCI cohortICI therapyCheckpoint inhibitorsCancer Genome AtlasClinical benefitCancer CenterCell carcinomaCell lungPredictive biomarkersDifferent cancer typesPoor responseWorse outcomesMSK-IMPACTMetastatic cancer